Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Burning Rock Biotech ( (BNR) ) is now available.
Burning Rock Biotech reported its financial results for the second quarter of 2025, showing a 9.6% increase in total revenues compared to the same period in 2024. The company achieved a gross profit of RMB108.1 million, a 13.3% increase from the previous year, and significantly reduced its net loss to RMB9.7 million from RMB108.0 million in 2024. The results reflect a strategic shift towards in-hospital testing and increased pharma R&D services, alongside effective cost control measures that reduced operating expenses by 42.1%.
The most recent analyst rating on (BNR) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Burning Rock Biotech stock, see the BNR Stock Forecast page.
Spark’s Take on BNR Stock
According to Spark, TipRanks’ AI Analyst, BNR is a Neutral.
The overall score is impacted primarily by financial challenges, including declining revenue and negative cash flow, despite the positive technical momentum. Valuation remains a concern due to ongoing losses. The lack of additional data from earnings calls or corporate events means the score is weighted heavily toward financial performance and technical analysis.
To see Spark’s full report on BNR stock, click here.
More about Burning Rock Biotech
Burning Rock Biotech Limited is a company focused on the application of next generation sequencing (NGS) technology in precision oncology. Its business includes NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has progressed beyond proof-of-concept R&D into clinical validation.
Average Trading Volume: 45,934
Technical Sentiment Signal: Buy
Current Market Cap: $89.32M
See more insights into BNR stock on TipRanks’ Stock Analysis page.